We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+67.45%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$315M
Cap. Flow
-$130M
Cap. Flow %
-5.88%
Top 10 Hldgs %
38.34%
Holding
95
New
23
Increased
27
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$74.6M
2
ABVX
Abivax
ABVX
+$61.3M
3
BDX icon
Becton Dickinson
BDX
+$55.7M
4
DXCM icon
DexCom
DXCM
+$51.4M
5
RGEN icon
Repligen
RGEN
+$48.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$108M
2
CYTK icon
Cytokinetics
CYTK
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$84M
4
QURE icon
uniQure
QURE
+$63.1M
5
KALV
KalVista Pharmaceuticals
KALV
+$54.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
51
PUT
Biohaven
BHVN
$2.21B
$10.5M 0.48%
+701,700
New +$10.2M
INSP icon
52
Inspire Medical Systems
INSP
$1.74B
$10M 0.45%
+135,000
New +$13.7M
KALV
53
DELISTED
KalVista Pharmaceuticals
KALV
$9.13M 0.41%
750,000
-3,925,000
-84% -$54.2M
LNTH icon
54
Lantheus
LNTH
$6.59B
$8.72M 0.39%
170,000
+120,000
+240% +$7.5M
APLT
55
DELISTED
Applied Therapeutics
APLT
$8.62M 0.39%
14,250,000
+2,750,000
+24% +$1.3M
CGON icon
56
CG Oncology
CGON
$6.62B
$7.05M 0.32%
+175,000
New +$5.09M
VYGR icon
57
Voyager Therapeutics
VYGR
$198M
$6.89M 0.31%
1,475,000
– –
TVRD
58
Tvardi Therapeutics
TVRD
$23.4M
$6.51M 0.29%
+167,000
New +$4.75M
VTYX
59
DELISTED
Ventyx Biosciences
VTYX
$6.38M 0.29%
2,050,000
+50,000
+3% +$132K
GLUE icon
60
Monte Rosa Therapeutics
GLUE
$1.34B
$5.93M 0.27%
+800,000
New +$4.24M
GSK icon
61
GSK
GSK
$106B
$5.39M 0.24%
+125,000
New +$4.88M
NVCR icon
62
NovoCure
NVCR
$1.91B
$5.17M 0.23%
+400,000
New +$5.34M
AGIO icon
63
Agios Pharmaceuticals
AGIO
$1.93B
$5.1M 0.23%
+127,000
New +$4.78M
NYXH
64
Nyxoah
NYXH
$147M
$5.09M 0.23%
1,107,413
-294,589
-21% -$1.93M
MYGN icon
65
Myriad Genetics
MYGN
$312M
$4.34M 0.2%
+600,000
New +$3.56M
EXAS
66
DELISTED
Exact Sciences
EXAS
$4.1M 0.19%
75,000
-625,000
-89% -$31.2M
ESTA icon
67
Establishment Labs
ESTA
$2.28B
$4.1M 0.19%
+100,000
New +$4.08M
KOD icon
68
Kodiak Sciences
KOD
$2.84B
$4.09M 0.18%
+250,000
New +$2.15M
ANRO icon
69
Alto Neuroscience
ANRO
$1.11B
$3.82M 0.17%
950,000
– –
ARQT icon
70
Arcutis Biotherapeutics
ARQT
$3.18B
$3.77M 0.17%
200,000
+105,000
+111% +$1.66M
RCUS icon
71
Arcus Biosciences
RCUS
$3.64B
$3.4M 0.15%
+250,000
New +$2.6M
FATE icon
72
Fate Therapeutics
FATE
$326M
$3.17M 0.14%
2,515,000
– –
ALEC icon
73
Alector
ALEC
$198M
$2.9M 0.13%
980,000
+3,008
+0.3% +$6.63K
ENGN icon
74
enGene Therapeutics
ENGN
$121M
$2.53M 0.11%
370,000
– –
PASG icon
75
Passage Bio
PASG
$14.1M
$2.45M 0.11%
305,000
– –
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Vestal Point Capital held 95 positions worth $2.21B, up 17% from $1.9B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Vestal Point Capital withdrew a net $130M in Q3 2025, closing 14 positions and reducing 21 holdings. Its most notable exit was GE HealthCare, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Abivax worth $84.9M.

  • Vestal Point Capital's largest Q3 2025 buy was Abivax: 1,000,000 shares worth $84.9M.
  • Vestal Point Capital added most to Ascendis Pharma A/S in Q3 2025, an estimated $74.6M increase.
  • Vestal Point Capital's biggest Q3 2025 reduction was Arcellx, cutting an estimated $108M.
  • Vestal Point Capital fully exited GE HealthCare in Q3 2025, selling an estimated $51.8M.
  • Vestal Point Capital's ten largest holdings make up 38% of its $2.21B portfolio in Q3 2025.
  • Vestal Point Capital opened 23 new positions and closed 14 in Q3 2025.
  • Vestal Point Capital's portfolio value rose 17% quarter-over-quarter to $2.21B.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.